Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Neurofibroma, Plexiform 1Nerve Sheath Neoplasms 1Lymphedema 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × pirfenidone × Clear all
NCT04243837 2024-04-23

LYT-100 in Patients With BCRL

PureTech

Phase 2 Terminated
50 enrolled 9 charts

Lymphedema

NCT00076102 2018-04-23

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
36 enrolled 13 charts
CNS

Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡